[ad_1]
(Reuters) – The U.S. Food and Drug Administration on Monday issued a warning to healthcare providers against administering malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences’ experimental COVID-19 drug, remdesivir.
The agency said the co-administration may result in reduced antiviral activity of remdesivir. (reut.rs/30I9w1O)
Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli
Our Standards:The Thomson Reuters Trust Principles.
[ad_2]
Source link